Abstract
Diosmetin (Dios), a flavone aglycone, is a major active ingredient of many herbal medicines. Previous studies implicated that the potential antitumor activities of Dios are mediated through multiple cell signaling pathways, however more investigations are required to reveal the targets and mechanisms of Dios. In this study, our results demonstrated that cell cycle progression and proliferation of HepG2 cells were inhibited by Dios. Meanwhile, Dios-induced liver cancer cell apoptosis was related with the p53 activation. After PFT-α, a p53 inhibitor was added into Dios-treated HepG2 cells, cell growth inhibition was partially reversed. These findings defined and supported that p53 is a novel target of Dios. By activating p53, Dios exerts anticancer effects by inducing cell cycle arrest and apoptosis in HepG2 cells.
Keywords: Diosmetin, HepG2, P53, apoptosis, flavonoids, ERK and JNK phosphorylation.
Protein & Peptide Letters
Title:Diosmetin, a Potential p53 Activator, Performs Anticancer Effect by Regulating Cell Cycling and Cell Proliferation in HepG2 Cells
Volume: 24 Issue: 5
Author(s): Bin Liu*, Miaomiao Zhang, Shuna Liu, Jie Ying, Jingjing Zhang, Hiroshi Kurihara, Weiqiang Zheng, Rong-Rong He*Runzhi Zhu
Affiliation:
- Infection department of Internal Medicine, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, Guangdong Province,China
- College of Pharmacy, Jinan University, Guangzhou 510632, Guangdong Province,China
Keywords: Diosmetin, HepG2, P53, apoptosis, flavonoids, ERK and JNK phosphorylation.
Abstract: Diosmetin (Dios), a flavone aglycone, is a major active ingredient of many herbal medicines. Previous studies implicated that the potential antitumor activities of Dios are mediated through multiple cell signaling pathways, however more investigations are required to reveal the targets and mechanisms of Dios. In this study, our results demonstrated that cell cycle progression and proliferation of HepG2 cells were inhibited by Dios. Meanwhile, Dios-induced liver cancer cell apoptosis was related with the p53 activation. After PFT-α, a p53 inhibitor was added into Dios-treated HepG2 cells, cell growth inhibition was partially reversed. These findings defined and supported that p53 is a novel target of Dios. By activating p53, Dios exerts anticancer effects by inducing cell cycle arrest and apoptosis in HepG2 cells.
Export Options
About this article
Cite this article as:
Liu Bin*, Zhang Miaomiao, Liu Shuna, Ying Jie, Zhang Jingjing, Kurihara Hiroshi, Zheng Weiqiang, He Rong-Rong*, Zhu Runzhi, Diosmetin, a Potential p53 Activator, Performs Anticancer Effect by Regulating Cell Cycling and Cell Proliferation in HepG2 Cells, Protein & Peptide Letters 2017; 24 (5) . https://dx.doi.org/10.2174/0929866524666170223094634
DOI https://dx.doi.org/10.2174/0929866524666170223094634 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Naturally Occurring δ-Hydroxy-γ-Lactones: Muricatacins and Related Compounds
Current Organic Chemistry Allosteric Inhibitors of Bcr-Abl: Towards Novel Myristate-Pocket Binders
Current Pharmaceutical Biotechnology Aurora B Kinase and Passenger Proteins as Targets for Cancer Therapy
Current Enzyme Inhibition Bone Metastasis-Related MicroRNAs: New Targets for Treatment?
Current Cancer Drug Targets Oncogenic MicroRNAs in the Genesis of Leukemia and Lymphoma
Current Pharmaceutical Design Neuroprotective Gene Therapy for the Treatment of Inherited Retinal Degeneration
Current Gene Therapy Anabolic Androgenic Steroids Abuse and Liver Toxicity
Mini-Reviews in Medicinal Chemistry Sporadic Porphyria in a Patient with Stage II Melanoma Treated with Interferon α
Current Drug Safety Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity
Medicinal Chemistry Reviews - Online (Discontinued) Base Excision Repair, the Redox Environment and Therapeutic Implications
Current Molecular Pharmacology A 1536-Well Fluorescence Polarization Assay to Screen for Modulators of the MUSASHI Family of RNA-Binding Proteins
Combinatorial Chemistry & High Throughput Screening Editorial [Hot Topic: Mechanisms of Drug Sensitivity and Resistance in Cancer (Guest Editor: Lorraine ODriscoll)]
Current Cancer Drug Targets Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Gene Therapy of Cancer with Interleukin-12
Current Pharmaceutical Design Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research Development of Decision Tree Models for Substrates, Inhibitors, and Inducers of P-Glycoprotein
Current Drug Metabolism Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
Current Medicinal Chemistry Learning from Metabolic Networks: Current Trends and Future Directions for Precision Medicine
Current Medicinal Chemistry Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Recent Patents on Anti-Cancer Drug Discovery